Member Info for stephen11

17-Jul-25 13:52:58 0.102 1,958,793 Buy* 0.095 0.105 1,996 O

17-Jul-25 13:52:38 0.101 2,913,910 Buy* 0.095 0.105 2,943 O

17-Jul-25 12:51:12 0.1184 7,366,917 Unknown* 0.095 0.105 8,722 O

17-Jul-25 13:51:01 0.101 1,000,000 Buy* 0.095 0.105 1,010 O

17-Jul-25 13:48:01 0.1014 192,308 Buy* 0.095 0.105 195.00 O

17-Jul-25 13:46:00 0.10199 98,534 Buy* 0.095 0.105 100.49 O

17-Jul-25 13:45:59 0.10199 1,847,107 Buy* 0.095 0.105 1,884 O

17-Jul-25 13:45:26 0.10199 300,000 Buy* 0.095 0.105 305.97 O

17-Jul-25 13:44:53 0.1023 971,700 Buy* 0.095 0.105 994.05 O

17-Jul-25 12:43:55 0.1055 10,000,000 Unknown* 0.095 0.105 10.55k O

17-Jul-25 13:43:37 0.1029 42,808 Buy* 0.095 0.105 44.05 O

17-Jul-25 13:43:25 0.103 1,000,000 Buy* 0.095 0.105 1,030 O

17-Jul-25 13:43:20 0.103 45,631 Buy* 0.095 0.105 47.00 O

The SP won't hold at these levels for long - pressure will be like stopping Niagara Falls with your hands.

Big break out soon.

GLA.

Stephen11.

Hi Guys,

You don't often see earning potential and associated revenue projections like this on AIM.

Coupled with such a low MCAP (4m approx), the stock watch sections in the print media will be all over this in the morning.

These low prices will be but a distant memory!

GLA.

Stephen11.

Any of you guys get into EME earlier today?

Its easy money and has a crazy low m-cap compared to potential revenue.

And more to come!

For once something has came good - really pleased for everyone!

A fill or kill order worked for me on HL earlier.

Not a crazy amount, but will provide a bit of sport.

Realistically, where could the SP and MCap settle based on earning potential?

GLA.

Stephen11.

Thanks for the info sharing John 👍.

An informative post Eureka - definitely brighter days ahead 😊.

Hi Jimi,

Thankyou for your info sharing and in particular your 3 point guide as below, for final sign-off of CYP2C19.

Do you think we will get these 3 messages spread over 3 RNS or could we get one mega RNS. And, if it’s the former, what might be the Timelapse between messages. Speculation I know, but maybe you or others have seen similar in the pharma sector?

It’s difficult to know how these regulatory bodies operate.

GLA.

Stephen11.

Last time I heard Budd had a role in a UK pharmacogenics promotional/regulation group. Not sure what Cheek is doing.

I’m also kicking myself for not buying more at 0.24p, but hindsight is a great thing.

Don’t post that often - bought in around the time of the Mali Coup 4/5 years ago.

This share has never been a worry due to the strong 💪 fundamentals.

Ps…and don’t forget the gold

Fire 🔥

Good assessments Jimi and Rud - thanks 👍

Is that based on the updated figure (stated by Gino) that the UK market is now worth £18million Jimi for CYP2C-19?

If so, with £8-9m from CYP2C19 and around a £1m from Scotland and more from MTRNR-1 —— what might the SP be with revenues of £10m annually?

I’m not saying the NHS is Manchester. However, it has been prudent of GDR to trial the effectiveness of the MTRNR-1 and CYP2C19 in one region to demonstrate its potential at a national level.

The main issue is the convoluted procurement procedures of the NHS, not the speed, efficiency, or accuracy, and superiority of the test.

These issues will be sorted with National Commissioning.

And, please Stockloss - we don’t need a history lesson about the hepatitis test.

GLA.

Stephen11.

I’d be keen to hear your rationale and evidence to support your claim that the NHS don’t like POC testing Stocksaint?

The media coverage from Manchester NHS documenting the premature babies who have been saved from lifelong hearing loss would suggest otherwise?

And please - feel free to reply, although please provide more than your normal anecdotal evidence.

GLA.

Stephen11.

A mother, father, or the clinicians of a premature baby would disagree with lab testing. And so would a stroke patient and the clinicians who would fear a secondary TIA.

These cohorts need timely intervention, in case, like a sizeable proportion of the population, they would have adverse drug reactions to certain well known meds. This leads to more time in hospital and a downstream cost to the NHS.

3-5 days waiting in a queue at a lab won’t cut it - but a result and the correct meds in 26 mins or an hour would. The empirical evidence on this couldn’t be any clearer and I’m not sure why some still debate this.

These are tests created for the NHS with NHS support.

National Commissioning will come.

GLA.

Stephen11.

I don’t think 🤔 a share consolidation is likely, or even a remote possibility.

Between 90-95% of the company is owned by private shareholders - many of whom have high average share prices. I can’t see 75% of them voting to dilute their own shares. Additionally, an extra ordinary general meeting would be required

Anyways, before more cash is needed - in October 2025, or nearer to Christmas, we’ll have a much higher SP, as sales will be rolling in from National Commissioning of the CYP2C19 Stroke Assay.

GLA.

Stephen11.

Hi folks,

I’m in the med for a few weeks and only got a chance to listen to Gino’s presentation just now. Very impressive - my take home messages:

- 95% of the entire population have at least one DNA variant that would create an adverse drug reaction to a variety of well known medications 💊. I’d say the future of phamacogenetic interventions is bright

- News on CYP2C19 National Commissioning is imminent. Gino said it was due any day now.

- Interestingly, clinicians and parents would like ALL babies, and not just premature ones to be tested for the MTRNR-1 variant. This, if adopted would dramatically increase market potential

- Really encouraged to hear of sales in Saudi Arabia - the private Middle Eastern health market is huge.

Good luck all,

Stephen11.

Ps….big thankyou to JimiHendrix, Eureka, Lionel, Bighammer and others for the info sharing and positivity 😀